SynthesisCardiovascular engineering and technology2025
Comparative Technological Analysis of Durability and Reliability in Axial-Flow Pump Left Ventricular Assist Devices (LVADs).
Synthesis in Cardiovascular engineering and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis study addresses the critical gap in the literature regarding the comparative analysis of axial flow left ventricular assist devices (LVADs). Despite technological advancements, there is a notable lack of integrated studies focusing solely on axial flow pumps and comparing multiple models with the same technology. This gap limits developers' access to comprehensive technical information essential for innovation in mechanical design, flow efficiency, and thrombus prevention.
methodA systematic review of 27 low-risk studies was performed on four axial flow LVADs: HeartMate II, DeBakey, Berlin Heart INCOR, and Jarvik 2000. The analysis evaluated durability and reliability using key metrics, including actuarial survival rates, device exchange rates, pump thrombosis rates, and freedom from adverse events, while considering technical factors such as rotor design, flow dynamics, and material innovation.
resultsHeartMate II achieved a 79% actuarial survival rate at 1 year and a 6.3% thrombosis-related exchange rate. DeBakey had a higher exchange rate of 33.3% due to mechanical issues, indicating a need for better material durability. Jarvik 2000 offered long-term support with a 5-year duration and an 8.3% thrombosis rate, benefiting from its spiral cable design. INCOR showed high reliability with low energy consumption and minimal driveline infections, highlighting the advantages of advanced coatings and reduced friction.
conclusionAxial flow LVADs are crucial for patients with small chest spaces, especially children. Enhancements in rotor design, materials, and real-time monitoring are essential for improving durability and reliability. These findings provide valuable insights for developing more durable and reliable axial flow pumps.
Indexed as
Identifiers
40307660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.